Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis? Evaluation of: Zhang X, Huang Y, Navarro M, et al. A proof-of-concept and drug-drug interaction of pamapimod, a novel p38 MAP kinase inhibitor, with
|
PDF
(272kB)
c38312.pdf. |
Description
Background: Methotrexate alone or in combination with other agents is the standard treatment for moderate-to-severe rheumatoid arthritis. As the biological agents are expensive, they are not usually used until methotrexate has failed to give a good response. Thus, there is scope for the development of cheaper drugs that can be used instead of methotrexate or in addition to methotrexate. Objectives/methods: Pamapimod is a p38α inhibitor being developed for use in the treatment of rheumatoid arthritis. The objective was to evaluate the recent clinical trials of pamapimod in subjects with rheumatoid arthritis. Results: There is no clear cut evidence that pamapimod alone or in the presence of methotrexate is efficacious in subjects with rheumatoid arthritis, but it does cause adverse effects. Conclusion: It is unlikely that pamapimod will be useful in the treatment of rheumatoid arthritis.
Impact and interest:
Citation counts are sourced monthly from Scopus and Web of Science® citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.
Full-text downloads:
Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.
ID Code: | 38312 | ||||
---|---|---|---|---|---|
Item Type: | Contribution to Journal (Journal Article) | ||||
Refereed: | Yes | ||||
ORCID iD: |
|
||||
Measurements or Duration: | 6 pages | ||||
Keywords: | clinical trials, methotrexate, p38a inhibition, pamapimod, pharmacokinetics, rheumatoid arthritis | ||||
DOI: | 10.1517/14656566.2010.507631 | ||||
ISSN: | 1465-6566 | ||||
Pure ID: | 32202104 | ||||
Divisions: | Past > QUT Faculties & Divisions > Faculty of Health Past > QUT Faculties & Divisions > Faculty of Science and Technology |
||||
Copyright Owner: | Consult author(s) regarding copyright matters | ||||
Copyright Statement: | This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au | ||||
Deposited On: | 03 Nov 2010 03:53 | ||||
Last Modified: | 02 Mar 2024 06:35 |
Export: EndNote | Dublin Core | BibTeX
Repository Staff Only: item control page